The approval of the first COVID-19 vaccine came at a breakneck speed in December. Inoculation started in the US, liberating pent-up hopes that virus-ravaged states could get past the pandemic that has killed over 1.5 million people across continents.
Body mass index (BMI) levels both above and below 25.0–29.9 kg/m2 are associated with increased mortality in a population without pre-existing disease, suggesting that the current cutoff of overweight (BMI ≥23 kg/m2) may need re-evaluation and that BMI alone may not be an accurate measure for indicating adiposity in Asians, according to a prospective cohort study in Korea.
The oldest patients get as much cardioprotective benefit from reducing low-density lipoprotein (LDL) cholesterol levels as younger patients, according to a study, suggesting that age should pose no barrier to the use of lipid-lowering treatments.
Use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor sotagliflozin led to a reduction in the risk of deaths from cardiovascular (CV) causes, hospitalizations for heart failure (HF), and urgent visits for HF compared with placebo among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) regardless of the degree of albuminuria, the SCORED* trial has shown.
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
Consumption of a diet rich in flavonoids, found in almost all fruits and vegetables, can lower the risk of hospitalization for peripheral artery disease (PAD), revascularizations or endovascular surgery, and lower extremity amputations, according to a study.
New drug applications approved by US FDA as of 01 - 15 January 2021 which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Administering benzodiazepines during an acute coronary syndrome (ACS) may spell trouble for patients, with a recent study showing that despite rapidly relieving anxiety, the drug can also contribute to increased risk of post-traumatic stress disorder (PTSD) symptoms.
Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.